Shifting Dynamics in FDA Approvals

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these firms are bringing to the market.

In this week’s episode of “The Top Line,” we take a deep dive into the FDA’s list of drugs that were approved in 2024. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss why biotechs emerged with more approvals than large drugmakers and which new drugs figure to have the most impact for patients.

To learn more about the topics in this episode:

• 2024 drug approvals: Small companies loom large with several key FDA nods 

• For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been 

• 2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer

This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.

See omnystudio.com/listener for privacy information.